Sofituzumab Vedotin
- Product NameSofituzumab Vedotin
- CAS1418200-58-4
- CBNumberCB78080896
- MW0
- MOL FileMol file
- MSDS FileSDS
Sofituzumab Vedotin Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0628998 | 1mg | $1029 | Sofituzumab vedotin 98.97% |
Buy |
| ChemScene CS-0628998 | 5mg | $2578 | Sofituzumab vedotin 98.97% |
Buy |
| ChemScene CS-0628998 | 10mg | $4117 | Sofituzumab vedotin 98.97% |
Buy |
| aablocks AA02E6G3 | 1mg | $1510 | Sofituzumab vedotin ≥90%(SDS-PAGE&SEC-HPLC) |
Buy |
| aablocks AA02E6G3 | 5mg | $3776 | Sofituzumab vedotin ≥90%(SDS-PAGE&SEC-HPLC) |
Buy |
Sofituzumab Vedotin Chemical Properties,Usage,Production
Uses
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].in vivo
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].
| Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts[3] |
| Dosage: | 2.8 mg/kg |
| Administration: | IV, once weekly for 4 total doses |
| Result: | Improved survival. |
| Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3] |
| Dosage: | 2 mg/kg |
| Administration: | IV, once weekly for 3 total doses |
| Result: | Significantly decreased the tumor volume. |
References
[1] Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. DOI:10.3390/cancers12082223[2] Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. DOI:10.1093/annonc/mdw401
[3] Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32. DOI:10.1158/0008-5472.CAN-06-4512
Preparation Products And Raw materials
Sofituzumab Vedotin Suppliers
Global(15)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 18916372613 | yanzihan@shyuanye.com | China | 87240 | 60 | |
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 8000 | 62 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10300 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27756 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 027-65317797 13667154760 |
1096814016@qq.com | China | 10711 | 58 | |
| 15111215862 18229892877 |
3062105966@qq.com | China | 5571 | 58 | |
| 4000880777 17585207275 |
guojing@bioleaper.com | China | 5616 | 58 | |
| 17316404525 17316404525 |
209533805@qq.com | China | 9769 | 58 |
1418200-58-4, Sofituzumab VedotinRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine